Top Markets
Coin of the day
INOVIQ Ltd INOVIQ Ltd

INOVIQ Ltd

IIQ
Rang in aandelen #29964
INOVIQ Ltd specializes in the research, development, and commercialization of... INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Aandeelprijs
$0.13400411
Marktkapitalisatie
$18.86M
Verandering (1 dag)
2.70%
Verandering (1 jaar)
-48.10%
Land
AU
Handel INOVIQ Ltd (IIQ)

Categorie

P/B-ratio voor INOVIQ Ltd (IIQ)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van INOVIQ Ltd is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor INOVIQ Ltd van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
4.1431 -
US
2.7156 -
US
- -
CN
24.3791 -
US
27.366 -
US